Summary
4.57 -0.10(-2.04%)07/05/2024
Editas Medicine Inc (EDIT)
Editas Medicine Inc (EDIT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.83 | -2.35 | -18.70 | -31.92 | -49.78 | -44.87 | -81.03 | -74.92 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.57 | |
| Open | 4.66 | |
| High | 4.66 | |
| Low | 4.50 | |
| Volume | 1,062,307 | |
| Change | -0.09 | |
| Change % | -1.83 | |
| Avg Volume (20 Days) | 1,799,549 | |
| Volume/Avg Volume (20 Days) Ratio | 0.59 | |
| 52 Week Range | 4.45 - 11.69 | |
| Price vs 52 Week High | -60.95% | |
| Price vs 52 Week Low | 2.58% | |
| Range | -2.04 | |
| Gap Up/Down | -0.08 | |
Fundamentals | ||
| Market Capitalization (Mln) | 377 | |
| EBIDTA | -106,383,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 52.07 | |
| Book Value | 8.6750 | |
| Earnings Per Share | -3.2310 | |
| EPS Estimate Current Quarter | -0.8200 | |
| EPS Estimate Next Quarter | -0.8600 | |
| EPS Estimate Current Year | -3.0600 | |
| EPS Estimate Next Year | -3.3300 | |
| Diluted EPS (TTM) | -3.2310 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -8.8760 | |
| Return on asset (TTM) | -0.2068 | |
| Return on equity (TTM) | -0.4155 | |
| Revenue TTM | 24,494,000 | |
| Revenue per share TTM | 0.3710 | |
| Quarterly Revenue Growth (YOY) | -0.9010 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -67,264,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3815 | |
| Revenue Enterprise Value | 59.4061 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 68,398,496 | |
| Shares Float | 66,684,099 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.32 | |
| Institutions (%) | 74.50 | |
06/26 21:33 EST - investorplace.com
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
06/25 08:00 EST - investorplace.com
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.
06/17 09:15 EST - zacks.com
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
06/14 03:01 EST - globenewswire.com
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
06/14 03:00 EST - globenewswire.com
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion
05/15 20:25 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 2:05 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets Luca Issi Thanks, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets.
Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 2:05 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets Luca Issi Thanks, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets.
05/14 10:00 EST - globenewswire.com
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.
05/10 06:00 EST - globenewswire.com
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications
05/09 13:41 EST - zacks.com
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
05/09 13:12 EST - fool.com
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Even after a slight price target reduction, the analyst feels the biotech's shares could see a major pop. In her view, management has devised the right strategy for developing its investigational products.
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Even after a slight price target reduction, the analyst feels the biotech's shares could see a major pop. In her view, management has devised the right strategy for developing its investigational products.
05/08 10:57 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - CSO Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Joon Lee - Truist Securities Mary Kate Davis - Bank of America Jack Allen - Baird Gena Wang - Barclays Brian Cheng - JPMorgan Eric Schmidt - Cantor Fitzgerald Jay Olson - Oppenheimer & Company Yanan Zhu - Wells Fargo Luca Issi - RBC Capital Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Editas Medicine's First Quarter 2024 Conference Call. All participants are now in a listen-only mode.
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - CSO Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Joon Lee - Truist Securities Mary Kate Davis - Bank of America Jack Allen - Baird Gena Wang - Barclays Brian Cheng - JPMorgan Eric Schmidt - Cantor Fitzgerald Jay Olson - Oppenheimer & Company Yanan Zhu - Wells Fargo Luca Issi - RBC Capital Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Editas Medicine's First Quarter 2024 Conference Call. All participants are now in a listen-only mode.
05/08 09:25 EST - zacks.com
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.71 per share a year ago.
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.71 per share a year ago.
05/08 07:00 EST - globenewswire.com
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease
05/02 07:00 EST - globenewswire.com
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update.
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update.
05/01 08:00 EST - globenewswire.com
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
04/26 11:05 EST - zacks.com
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/22 16:31 EST - globenewswire.com
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.
03/29 12:36 EST - zacks.com
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
03/13 19:58 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
03/12 15:56 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)